PIK3CB and ovarian carcinoma: A further study in multiple ovarian cell lines with differing PI3K or RAS/RAF pathway alterations, RB1 loss and wild-type for the alterations mentioned, demonstrated synergistic effects of MK-2206 and MEK (PD0325901) inhibitors in PI3K- and RAS-activated ovarian cancer cell lines and xenografts[138].